Shelf-stable mRNA delivery system targets bladder cancer cells without immune response

Published, peer-reviewed research shows a patent-pending, virus-mimicking platform technology developed at Purdue University ...
Drug Target Review

Virus-mimicking LENN nanoparticles deliver mRNA to bladder cancer cells

Explore LENN nanoparticles, a groundbreaking technology for delivering mRNA therapies to bladder cancer cells with enhanced ...
Targeted Oncology

Phase I Trial of Neoantigen Vaccine Shows 100% DFS Rate in HNSCC

Findings from a phase I trial (NCT04183166) evaluating TG4050, a neoantigen therapeutic vaccine, in patients with operable, ...

A new nanorobot designed to improve immune cell recognition could help treat colorectal cancer

Colorectal cancer, the abnormal growth of cancerous cells in the large intestine or the rectum, is one of the most common ...
Business Wire

ViroCell Manufactured a GMP Lentiviral Vector for UCL to Accelerate Research Into Prevention of Relapse in Childhood Blood Cancer

LONDON & NEW YORK--(BUSINESS WIRE)--ViroCell Biologics (“ViroCell” or the “Company”), a specialist viral vector Contract Development and Manufacturing Organisation (“CDMO”) for cell and gene therapy ...
News-Medical.Net on MSN

Purdue-developed LENN system enhances stability and targeting of mRNA cancer therapies

Published, peer-reviewed research shows a patent-pending, virus-mimicking platform technology developed at Purdue University ...